Biotechnology company Destiny Pharma said it had entered into a collaboration agreement with SporeGen to co-develop a preventive treatment for COVID-19. Under the agreement, the parties would share any costs and commercial returns from the potential Covid-19 treatment and plan to complete a pre-clinical programme with the aim of being ready to enter the first human clinical trials within 18 months. The SPOR‑COV product consisted of a formulation of Bacillus bacteria that would be administered nasally as a spray. Destiny Pharma and SporeGen were awarded a grant of £800,000 to fund the majority of the £1m cost of the initial SPOR-COV programme. At 8:15am: (LON:DEST) Destiny Pharma Plc share price was +7.5p at 56.5p
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.